174 related articles for article (PubMed ID: 35156326)
21. An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.
Wang L; Leite de Oliveira R; Huijberts S; Bosdriesz E; Pencheva N; Brunen D; Bosma A; Song JY; Zevenhoven J; Los-de Vries GT; Horlings H; Nuijen B; Beijnen JH; Schellens JHM; Bernards R
Cell; 2018 May; 173(6):1413-1425.e14. PubMed ID: 29754815
[TBL] [Abstract][Full Text] [Related]
22. Targeted therapy for melanoma: rational combinatorial approaches.
Kwong LN; Davies MA
Oncogene; 2014 Jan; 33(1):1-9. PubMed ID: 23416974
[TBL] [Abstract][Full Text] [Related]
23. Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.
Porcelli L; Mazzotta A; Garofoli M; Di Fonte R; Guida G; Guida M; Tommasi S; Azzariti A
Biomed Pharmacother; 2021 Jan; 133():111006. PubMed ID: 33202284
[TBL] [Abstract][Full Text] [Related]
24. AMBRA1 levels predict resistance to MAPK inhibitors in melanoma.
Di Leo L; Pagliuca C; Kishk A; Rizza S; Tsiavou C; Pecorari C; Dahl C; Pacheco MP; Tholstrup R; Brewer JR; Berico P; Hernando E; Cecconi F; Ballotti R; Bertolotto C; Filomeni G; Gjerstorff MF; Sauter T; Lovat P; Guldberg P; De Zio D
Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2400566121. PubMed ID: 38870061
[TBL] [Abstract][Full Text] [Related]
25. Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells.
Kozar I; Cesi G; Margue C; Philippidou D; Kreis S
Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt B):2980-2992. PubMed ID: 28408301
[TBL] [Abstract][Full Text] [Related]
26. Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.
Hartman ML; Sztiller-Sikorska M; Gajos-Michniewicz A; Czyz M
Cells; 2020 Jan; 9(1):. PubMed ID: 31936151
[TBL] [Abstract][Full Text] [Related]
27. Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents.
Rossi A; Roberto M; Panebianco M; Botticelli A; Mazzuca F; Marchetti P
Eur J Pharmacol; 2019 Nov; 862():172621. PubMed ID: 31446019
[TBL] [Abstract][Full Text] [Related]
28. Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma.
Lo RS; Shi H
Methods Mol Biol; 2014; 1102():163-74. PubMed ID: 24258979
[TBL] [Abstract][Full Text] [Related]
29. SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma.
Hüser L; Sachindra S; Granados K; Federico A; Larribère L; Novak D; Umansky V; Altevogt P; Utikal J
Int J Cancer; 2018 Dec; 143(12):3131-3142. PubMed ID: 29905375
[TBL] [Abstract][Full Text] [Related]
30. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
Welsh SJ; Rizos H; Scolyer RA; Long GV
Eur J Cancer; 2016 Jul; 62():76-85. PubMed ID: 27232329
[TBL] [Abstract][Full Text] [Related]
31. In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma.
Fattore L; Campani V; Ruggiero CF; Salvati V; Liguoro D; Scotti L; Botti G; Ascierto PA; Mancini R; De Rosa G; Ciliberto G
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32178301
[TBL] [Abstract][Full Text] [Related]
32. [Treatment of BRAF-mutated metastatic melanoma].
Boyles TB; Svane IM; Bastholt L; Schmidt H
Ugeskr Laeger; 2016 Aug; 178(35):. PubMed ID: 27592869
[TBL] [Abstract][Full Text] [Related]
33. MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy.
Tran KA; Cheng MY; Mitra A; Ogawa H; Shi VY; Olney LP; Kloxin AM; Maverakis E
Drug Des Devel Ther; 2016; 10():43-52. PubMed ID: 26730180
[TBL] [Abstract][Full Text] [Related]
34. A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy.
Lelliott EJ; Cullinane C; Martin CA; Walker R; Ramsbottom KM; Souza-Fonseca-Guimaraes F; Abuhammad S; Michie J; Kirby L; Young RJ; Slater A; Lau P; Meeth K; Oliaro J; Haynes N; McArthur GA; Sheppard KE
Sci Rep; 2019 Feb; 9(1):1225. PubMed ID: 30718660
[TBL] [Abstract][Full Text] [Related]
35. Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma.
Cohen JV; Sullivan RJ
Clin Cancer Res; 2019 Oct; 25(19):5735-5742. PubMed ID: 30992297
[TBL] [Abstract][Full Text] [Related]
36. Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma.
Patel A; Garcia LF; Mannella V; Gammon L; Borg TM; Maffucci T; Scatolini M; Chiorino G; Vergani E; Rodolfo M; Maurichi A; Posch C; Matin RN; Harwood CA; Bergamaschi D
Cancer Res; 2020 Jun; 80(12):2676-2688. PubMed ID: 32291316
[TBL] [Abstract][Full Text] [Related]
37. A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma.
Nagler A; Vredevoogd DW; Alon M; Cheng PF; Trabish S; Kalaora S; Arafeh R; Goldin V; Levesque MP; Peeper DS; Samuels Y
Pigment Cell Melanoma Res; 2020 Mar; 33(2):334-344. PubMed ID: 31549767
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?
Schummer P; Schilling B; Gesierich A
Am J Clin Dermatol; 2020 Aug; 21(4):493-504. PubMed ID: 32124332
[TBL] [Abstract][Full Text] [Related]
39. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
40. The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells.
Whipple CA; Boni A; Fisher JL; Hampton TH; Tsongalis GJ; Mellinger DL; Yan S; Tafe LJ; Brinckerhoff CE; Turk MJ; Mullins DW; Fadul CE; Ernstoff MS
Melanoma Res; 2016 Jun; 26(3):223-35. PubMed ID: 26974965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
